Low-Dose Treatment With Interleukin-2 Across Multiple Studies Shows Benefits in Chronic Graft-Versus-Host Disease
December 10, 2017
December 10, 2017
BOSTON, Massachusetts, Dec. 10 -- The Dana-Farber Cancer Institute issued the following news release:
Daily low doses of the immune signaling protein interleukin-2 (IL-2) can safely benefit patients who develop chronic graft-versus-host disease following stem cell transplants, including particular benefit in pediatric patients in one small study, report scientists from Dana-Farber Cancer Institute.
Dana-Farber researchers, who have pioneered the use of IL-2 in post-tran . . .
Daily low doses of the immune signaling protein interleukin-2 (IL-2) can safely benefit patients who develop chronic graft-versus-host disease following stem cell transplants, including particular benefit in pediatric patients in one small study, report scientists from Dana-Farber Cancer Institute.
Dana-Farber researchers, who have pioneered the use of IL-2 in post-tran . . .